Lv7177
4320 积分 2021-09-07 加入
Multiple myeloma
19小时前
已完结
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
5天前
已完结
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
6天前
已完结
ADME investigations of novel therapeutic modalities: challenges and opportunities 2025
7天前
已完结
B7-H3 as a Universal Target for Solid Tumor Therapy: Clinical Promise and Biological Complexity
7天前
已完结
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
8天前
已完结
Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape
12天前
已完结
BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape
13天前
已完结
Current landscape and future prospects of bispecific antibodies in multiple myeloma
13天前
已完结
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM)
13天前
已完结
皖公网安备34019202002308
